Compare RYTM & AN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | AN |
|---|---|---|
| Founded | 2008 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.4B |
| IPO Year | 2017 | 1995 |
| Metric | RYTM | AN |
|---|---|---|
| Price | $93.66 | $185.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 9 |
| Target Price | $131.14 | ★ $244.33 |
| AVG Volume (30 Days) | ★ 555.5K | 313.9K |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.34 | 0.71 |
| EPS | N/A | ★ 5.85 |
| Revenue | N/A | ★ $27,631,400,000.00 |
| Revenue This Year | $55.34 | $4.32 |
| Revenue Next Year | $86.06 | $2.89 |
| P/E Ratio | ★ N/A | $33.48 |
| Revenue Growth | N/A | ★ 3.24 |
| 52 Week Low | $60.99 | $176.62 |
| 52 Week High | $122.20 | $228.92 |
| Indicator | RYTM | AN |
|---|---|---|
| Relative Strength Index (RSI) | 62.82 | 42.44 |
| Support Level | $82.43 | $178.45 |
| Resistance Level | $100.69 | $215.56 |
| Average True Range (ATR) | 4.46 | 5.40 |
| MACD | 0.64 | 0.42 |
| Stochastic Oscillator | 81.49 | 4.75 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
AutoNation is the second-largest automotive dealer in the United States, with 2025 revenue of $27.6 billion and over 240 dealerships, plus 52 collision centers. The firm also has 26 AutoNation USA used-vehicle stores, a captive lender, four auction sites, and three parts distributors across 20 states primarily in Sunbelt metropolitan areas. New-vehicle sales account for nearly half of revenue; the company also sells used vehicles, parts, and repair services as well as auto financing. The company (formerly Republic Industries) divested its waste management unit (Republic Services) in 1999 and its car rental businesses (ANC Rental) in 2000. Wayne Huizenga founded the company in the 1990s to bring the rollup acquisition strategy to auto retailing, which has proved to be a smart move.